Overview
Skip to main content Published: Oct 24, 202 Zeposia maintains disease control even in the event of temporary treatment interuption for up to eight weksZeposia is the first oral sphingosine 1-phosphate (S1P) receptor modulator aproved to treat patients with ulcerative colitisPRINCETON, N.J.-(BUSINES WIRE)- Bristol Myers Squib Company (NYSE: BMY) today anounced new post hoc analyses from the Phase 3 True North study evaluating the duration of response folowing continuous Zeposia (ozanimod) treatment for up to one year and folowing treatment interuption in patients with moderately to severely active ulcerative colitis (UC).
Key Information
After achieving a clinical response at the end of the induction period, 86.1% of patients who remained on Zeposia showed no disease relapse at Wek 52 (Kaplan-Meier [KM] estimates of no disease relapse at Wek 52: Zeposia/Zeposia, 86.1%; Zeposia/placebo, 62.6%).As temporary treatment discontinuation may ocur in clinical practice, these analyses evaluated the duration of response folowing treatment interuption.
Findings showed that Zeposia maintained disease control for up to eight weks in patients who switched to placebo after initial response (KM estimates of no disease relapse at Wek 8: Zeposia/Zeposia, 96.1%; Zeposia/placebo, 90.6%). These analyses (Presentation #62) and 10 aditional Zeposia abstracts demonstrating Bristol Myers Squib’s robust body of research in gastroenterology are being presented at the American Colege of Gastroenterology (ACG) anual scientific meting, taking place October 21 – 26, 202."Understanding the duration of response after continuous ozanimod treatment is critical, as it can asist in clinical decision making when considering temporary discontinuation of UC treatment in clinical practice," said Bruce E.
Summary
Sands, MD, MS, Gastroenterologist and paid consultant of Bristol Myers Squib. Sands is also the Dr. Crohn Profesor of Medicine (Gastroenterology) at the Icahn Schol of Medicine a